RT Journal Article
SR Electronic
T1 Effectiveness of Stereotactic Body Radiotherapy in the Treatment of Inoperable Early-stage Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3615
OP 3619
VO 27
IS 5B
A1 M. SCORSETTI
A1 P. NAVARRIA
A1 A. FACOETTI
A1 P. LATTUADA
A1 G. URSO
A1 A. MIRANDOLA
A1 G.M. FERRAROLI
A1 M. ALLOISIO
A1 G. RAVASI
YR 2007
UL http://ar.iiarjournals.org/content/27/5B/3615.abstract
AB Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved